cbdMD, Inc. (YCBD) Income Statement
YCBD FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsYCBD revenue and net income
Where YCBD's revenue goes
FY2025Each bar shows an amount and its share of revenue. YCBD kept −10.6% of revenue as net income.
YCBD profit margins
YCBD growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −1.5% | −18.5% | −14.5% | +108.2% |
| Gross profit | +10.4% | −16.4% | −14.6% | +118.1% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
YCBD quarterly EPS vs estimates
cbdMD beat the analyst EPS estimate in 3 of the last 8 quarters.
YCBD income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $19.5M | $24.2M | $35.4M | $44.5M | $41.9M | $23.7M | $459,091 | $4.5M | $2.0M |
| Cost of revenue | $7.2M | $8.6M | $11.1M | $14.9M | $15.5M | $15.5M | $9.1M | $326,556 | $1.4M | $1.6M |
| Gross profit | $12.0M | $10.8M | $13.0M | $20.5M | $29.0M | $26.4M | $14.5M | $132,535 | $3.1M | $413,130 |
| Research & development | $33,856 | $39,021 | $173,038 | $633,392 | $1.4M | $424,450 | — | — | — | — |
| Sales, general & admin | $11.4M | $12.6M | $18.1M | $31.3M | $39.3M | $34.9M | $28.9M | $1.9M | — | — |
| Total operating expenses | $14.1M | $14.0M | $22.3M | $37.8M | $48.6M | $44.0M | $28.9M | $1.9M | $3.4M | $4.1M |
| Operating income | −$2.2M | −$3.2M | −$9.3M | −$17.3M | −$19.6M | −$17.6M | −$14.4M | −$1.8M | −$239,291 | −$3.7M |
| Interest income | — | — | $63,702 | $16,246 | — | $39,877 | $75,071 | — | $500,630 | $154,980 |
| Interest expense | — | $29,507 | — | $16,246 | $28,930 | $57.7M | $71.9M | $955 | $500,627 | $154,977 |
| Income before taxes | −$2.0M | −$3.7M | −$22.9M | −$70.1M | −$24.3M | $11.3M | −$47.8M | −$1.8M | −$1.4M | −$3.9M |
| Income taxes | — | — | $13.7M | $4.0M | −$895,000 | −$1.3M | −$2.4M | −$16,000 | $25,000 | $8,000 |
| Net income | −$2.0M | −$3.7M | −$22.9M | −$70.1M | −$23.4M | $12.6M | −$50.4M | −$412,075 | −$1.7M | −$3.4M |
| EBITDA | −$244,980 | −$1.9M | −$20.0M | −$67.1M | −$22.0M | −$15.7M | −$14.1M | −$1.6M | −$168,015 | −$3.7M |
| EPS (diluted) | −$3.95 | −$17.50 | −$39.32 | −$360.26 | −$81.11 | −$117.10 | −$458.77 | −$0.07 | −$0.16 | −$32.21 |
| Gross margin | 62.4% | 55.7% | 54.0% | 57.9% | 65.1% | 63.0% | 61.4% | 28.9% | 69.7% | 20.3% |
| Operating margin | −11.3% | −16.4% | −38.4% | −48.9% | −44.1% | −42.0% | −60.7% | −391.4% | −5.3% | −183.8% |
| Net margin | −10.6% | −19.0% | −95.0% | −198.0% | −52.6% | 30.1% | −213.2% | −89.8% | −38.9% | −165.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.6M | $5.6M | $5.0M | $4.7M | $4.6M | $4.7M | $5.1M | $4.6M | $5.2M | $4.4M | $5.4M | $5.7M |
| Cost of revenue | $2.5M | $2.6M | $2.0M | $1.9M | $1.8M | $1.8M | $1.7M | $2.1M | $2.1M | $2.1M | $2.1M | $2.2M |
| Gross profit | $3.0M | $3.0M | $3.0M | $2.8M | $2.8M | $3.0M | $3.4M | $2.5M | $3.1M | $2.3M | $3.3M | $3.5M |
| Research & development | $3,538 | $2,899 | $808 | $15,022 | $9,564 | $6,323 | $2,947 | $22,186 | $10,108 | $2,097 | $4,629 | $16,039 |
| Sales, general & admin | $4.2M | $3.6M | $2.8M | $2.8M | $3.0M | $2.9M | $2.7M | $2.8M | $3.0M | $3.2M | $3.2M | $2.7M |
| Total operating expenses | $4.2M | $3.8M | $3.3M | $3.5M | $3.7M | $3.4M | $3.5M | $2.8M | $3.5M | $3.8M | $4.3M | $5.5M |
| Operating income | −$1.1M | −$800,784 | −$286,288 | −$685,816 | −$904,686 | −$485,816 | −$86,272 | −$316,555 | −$382,028 | −$1.5M | −$998,236 | −$15.2M |
| Interest income | $3,275 | $2,806 | $3,157 | — | $9,414 | $7,642 | $11,404 | — | — | — | — | — |
| Interest expense | — | — | — | — | — | $7,642 | $11.4M | — | $12,741 | $18,399 | $418 | $32,311 |
| Income before taxes | −$1.1M | −$797,978 | −$283,131 | −$679,968 | −$895,272 | −$480,757 | $15,095 | −$152,799 | $459,737 | −$3.0M | −$996,501 | −$15.9M |
| Income taxes | — | $78.8M | $41.5M | — | — | $1.0M | $1.0M | — | $1.00B | $1.0M | $13.6M | $13.6M |
| Net income | −$1.1M | −$797,978 | −$283,131 | −$679,968 | −$895,272 | −$480,757 | $15,095 | −$152,799 | $459,737 | −$3.0M | −$996,501 | −$15.9M |
| EBITDA | −$689,359 | −$375,240 | $133,499 | −$247,431 | −$446,759 | $94,977 | $354,233 | $488,142 | $1.1M | −$2.4M | −$421,918 | $12.6M |
| EPS (diluted) | −$0.11 | −$0.08 | −$0.04 | −$0.08 | −$0.21 | −$1.90 | −$1.76 | −$0.29 | −$1.20 | −$10.80 | −$5.21 | −$1.21 |
| Gross margin | 54.7% | 53.3% | 59.8% | 58.8% | 61.5% | 62.3% | 66.5% | 53.9% | 60.2% | 52.3% | 60.9% | 62.1% |
| Operating margin | −20.4% | −14.2% | −5.7% | −14.5% | −19.6% | −10.2% | −1.7% | −6.9% | −7.4% | −34.1% | −18.6% | −266.5% |
| Net margin | −20.3% | −14.1% | −5.6% | −14.4% | −19.4% | −10.1% | 0.3% | −3.4% | 8.9% | −68.8% | −18.5% | −278.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in YCBD's financial statements (latest annual report filed December 19, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
YCBD financial results
In fiscal year 2025 (ended September 30, 2025), cbdMD reported revenue of $19.2 million, down 1.5% from the year before. It had a net loss of $2.0 million, a net profit margin of −10.6%. Diluted earnings per share came to −$3.95. Over five years revenue grew at an average rate of −14.5% a year.
See the YCBD stock overview for the latest quote and news, or the YCBD chart for price history and technical indicators.
YCBD income statement FAQ
What is cbdMD's annual revenue?
cbdMD reported total revenue of $19.2 million for fiscal year 2025, which ended on September 30, 2025. That was down 1.5% from $19.5 million the previous year.
Is cbdMD profitable?
No. cbdMD reported a net loss of $2.0 million in fiscal 2025, a net profit margin of −10.6%; its operating margin was −11.3%.
What is cbdMD's gross margin?
cbdMD's gross margin was 62.4% in fiscal 2025: for every $100 of revenue, cbdMD kept $62 after the direct cost of its products and services.
How much does cbdMD spend on research and development?
cbdMD spent $0.0 million on research and development in fiscal 2025, 0.2% of revenue.
How fast is cbdMD growing?
Revenue grew −14.5% a year on average over the last five fiscal years, from $41.9 million to $19.2 million.
What are cbdMD's earnings per share?
cbdMD earned $-3.95 per diluted share in fiscal 2025, compared with $-17.50 a year earlier.
When does cbdMD's fiscal year end?
cbdMD's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 19, 2025.